Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4
NCT01884402 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 770
Last updated 2014-09-04
Summary
Primary objective:
• Develop and validate a tool towards patients with chronic hepatitis C genotype 1 and 4 to allow optimize treatment.
Conditions
- Hepatitis C, Chronic
Interventions
- DRUG
-
Peginterferon alfa-2a
Treatment as usual clinical practice
- DRUG
-
Ribavirin
Treatment as usual clinical practice
Sponsors & Collaborators
-
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
lead OTHER
Principal Investigators
-
Manuel Romero-Gómez, Medicine · Hospital de Valme & ciberEHD
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-10-31
- Primary Completion
- 2014-05-31
- Completion
- 2014-08-31
Countries
- Spain
Study Locations
More Related Trials
-
Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated with Peginterferon Alpha-2a and Ribavirin
NCT01634919 ·Status: COMPLETED
-
Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
NCT00056862 ·Status: COMPLETED ·Phase: PHASE4
-
Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)
NCT02106156 ·Status: COMPLETED
-
Observational Study in HCV Chronic Infection
NCT01945008 ·Status: COMPLETED
-
A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)
NCT01280656 ·Status: COMPLETED
-
Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients
NCT00526448 ·Status: UNKNOWN ·Phase: PHASE4
-
HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b
NCT01342003 ·Status: COMPLETED
-
High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV
NCT00381953 ·Status: COMPLETED ·Phase: PHASE3
-
Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels
NCT00575627 ·Status: UNKNOWN ·Phase: PHASE4
-
High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
NCT00735969 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)
NCT00705666 ·Status: COMPLETED
-
Impact of the Sustained Viral Response of Chronic Hepatitis c After Treatment With Direct Action Antivirals
NCT05062408 ·Status: COMPLETED
-
Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced Fibrosis
NCT00840489 ·Status: TERMINATED ·Phase: PHASE2
-
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
NCT01732796 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis
NCT02732405 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection
NCT00192647 ·Status: COMPLETED ·Phase: PHASE4
-
Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Infected Egyptian Patients
NCT01758939 ·Status: UNKNOWN
-
Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients
NCT00553930 ·Status: COMPLETED ·Phase: PHASE4
-
An Extension Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
NCT00292084 ·Status: COMPLETED ·Phase: PHASE2
-
High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3
NCT00830609 ·Status: COMPLETED ·Phase: PHASE4
-
Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)
NCT01380938 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)
NCT00493805 ·Status: TERMINATED ·Phase: PHASE4
-
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
NCT00323804 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.
NCT01195181 ·Status: COMPLETED ·Phase: PHASE4
-
Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies
NCT00530972 ·Status: COMPLETED ·Phase: PHASE4